BR112023020348A2 - Regimes de dosagem de ceftibuteno - Google Patents
Regimes de dosagem de ceftibutenoInfo
- Publication number
- BR112023020348A2 BR112023020348A2 BR112023020348A BR112023020348A BR112023020348A2 BR 112023020348 A2 BR112023020348 A2 BR 112023020348A2 BR 112023020348 A BR112023020348 A BR 112023020348A BR 112023020348 A BR112023020348 A BR 112023020348A BR 112023020348 A2 BR112023020348 A2 BR 112023020348A2
- Authority
- BR
- Brazil
- Prior art keywords
- ceftibutene
- ceftibuten
- dosage regimes
- twice daily
- daily
- Prior art date
Links
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 title abstract 4
- 229960004086 ceftibuten Drugs 0.000 abstract 3
- 239000003781 beta lactamase inhibitor Substances 0.000 abstract 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 abstract 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170936P | 2021-04-05 | 2021-04-05 | |
| PCT/US2022/071479 WO2022217199A1 (en) | 2021-04-05 | 2022-03-31 | Ceftibuten dosing regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023020348A2 true BR112023020348A2 (pt) | 2023-11-21 |
Family
ID=83545863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023020348A BR112023020348A2 (pt) | 2021-04-05 | 2022-03-31 | Regimes de dosagem de ceftibuteno |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240197750A1 (enExample) |
| EP (1) | EP4319760A4 (enExample) |
| JP (1) | JP2024512793A (enExample) |
| KR (1) | KR20230167077A (enExample) |
| CN (1) | CN117157078A (enExample) |
| AU (1) | AU2022254114A1 (enExample) |
| BR (1) | BR112023020348A2 (enExample) |
| CA (1) | CA3212788A1 (enExample) |
| MX (1) | MX2023011483A (enExample) |
| TW (1) | TW202304430A (enExample) |
| WO (1) | WO2022217199A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017290060B2 (en) | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| US12636297B2 (en) | 2019-06-19 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US12637481B2 (en) | 2020-03-18 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| IL297458A (en) | 2020-05-05 | 2022-12-01 | Qpex Biopharma Inc | Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170252351A1 (en) * | 2015-01-24 | 2017-09-07 | Wockhardt Limited | Antibacterial Compositions |
| AU2017290060B2 (en) * | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| AU2017295866A1 (en) * | 2016-07-14 | 2019-01-17 | Achaogen, Inc. | Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections |
| SG11201901658PA (en) * | 2016-09-16 | 2019-04-29 | Entasis Therapeutics Ltd | Beta-lactamase inhibitor compounds |
| US10085999B1 (en) * | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
| WO2019093450A1 (ja) * | 2017-11-10 | 2019-05-16 | 塩野義製薬株式会社 | ジアザビシクロオクタン誘導体 |
| DK3886798T3 (da) * | 2018-11-29 | 2026-04-20 | Basilea Pharmaceutica Int Ag Allschwil | Kombinationssammensætninger, som omfatter en beta-lactamase-hæmmer, og anvendelser deraf |
| US12636297B2 (en) * | 2019-06-19 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP4021443A1 (en) * | 2019-08-29 | 2022-07-06 | Arixa Pharmaceuticals, Inc. | Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections |
-
2022
- 2022-03-31 EP EP22785621.8A patent/EP4319760A4/en active Pending
- 2022-03-31 US US18/553,769 patent/US20240197750A1/en active Pending
- 2022-03-31 BR BR112023020348A patent/BR112023020348A2/pt unknown
- 2022-03-31 KR KR1020237037971A patent/KR20230167077A/ko not_active Withdrawn
- 2022-03-31 JP JP2023561040A patent/JP2024512793A/ja active Pending
- 2022-03-31 AU AU2022254114A patent/AU2022254114A1/en not_active Abandoned
- 2022-03-31 CA CA3212788A patent/CA3212788A1/en active Pending
- 2022-03-31 WO PCT/US2022/071479 patent/WO2022217199A1/en not_active Ceased
- 2022-03-31 MX MX2023011483A patent/MX2023011483A/es unknown
- 2022-03-31 CN CN202280024764.7A patent/CN117157078A/zh active Pending
- 2022-04-01 TW TW111112897A patent/TW202304430A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023011483A (es) | 2023-10-03 |
| US20240197750A1 (en) | 2024-06-20 |
| EP4319760A1 (en) | 2024-02-14 |
| TW202304430A (zh) | 2023-02-01 |
| WO2022217199A1 (en) | 2022-10-13 |
| CN117157078A (zh) | 2023-12-01 |
| KR20230167077A (ko) | 2023-12-07 |
| CA3212788A1 (en) | 2022-10-13 |
| AU2022254114A1 (en) | 2023-09-21 |
| EP4319760A4 (en) | 2025-01-08 |
| JP2024512793A (ja) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Strawn et al. | Efficacy and tolerability of antidepressants in pediatric anxiety disorders: A systematic review and meta‐analysis | |
| BR112018068512A2 (pt) | métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3 | |
| BR112023021761A2 (pt) | Regime de dosagem de anti-ifnar1 para injeção subcutânea | |
| MX2024013788A (es) | Regimenes de dosificacion superior de g1t38 | |
| BR112021026292A2 (pt) | Cistationina beta sintase peguilada para terapia enzimática para tratamento de homocistinúria | |
| Citrome et al. | Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed | |
| BR112022026202A2 (pt) | Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona | |
| BR112021024664A2 (pt) | Tratamentos de angioedema hereditário | |
| BR112021008582A8 (pt) | Regime de dosagem de anticorpo anti-tigit para tratamento de câncer | |
| Vitiello et al. | The importance of antibiotic treatment duration in antimicrobial resistance | |
| BR112016007479A2 (pt) | regimes de dosagem de imunoconjugado de anti-folr1 | |
| WO2020047352A8 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| BR112021024073A2 (pt) | Métodos de tratamento de cânceres associados a um vírus com inibidores de histona desacetilase | |
| Toyama et al. | A randomized phase II study evaluating pyridoxine for the prevention of hand–foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer | |
| JOP20230219A1 (ar) | نظام جرعات سوتوراسيب | |
| BR112019008156A2 (pt) | métodos, composições e regimes de dosagem no tratamento ou prevenção de indicações relacionadas com interferon-gama | |
| EP4424709A3 (en) | Dosing regimen for anti-bcma agents | |
| MX2022002683A (es) | Metodo terapeutico o profilactico para diabetes usando medicamentos combinados. | |
| BR112022024533A2 (pt) | Formulação compreendendo daprodustat | |
| BRPI0510738A (pt) | métodos de tratar doenças com copolìmeros aleatórios | |
| CL2025002930A1 (es) | Programa de dosificación de un inhibidor de her.2 | |
| BRPI0716929A8 (pt) | tratamento de esclerose múltipla com campath-1h | |
| MX2024002566A (es) | Regimen de dosificacion para un inhibidor de tead. | |
| BR112022004670A2 (pt) | Dispositivo de computação e método implementado por computador | |
| BR112021018930A2 (pt) | Miriquizumabe para uso em um método de tratamento de doença de crohn |